ArticleCureus2024
Assessing the Effectiveness of Histaglobulin in Chronic Idiopathic Urticaria: A Retrospective Analysis at a Tertiary Care Hospital.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Histaglobulin in Allergic Diseases: A Systematic Review and Meta-Analysis with Implications for Allergic Rhinitis.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Chronic urticaria is a transient cutaneous disorder that waxes and wanes swiftly but, due to its periodic episodes, declines the quality of life of the affected individuals. It is of two types: chronic spontaneous or idiopathic and chronic-induced urticaria. Urticaria can have many different causes, but one of the most common causes of chronic idiopathic urticaria (CIU) is autoimmune. Subcutaneous injection of histaglobulin has been used for a few decades to pacify various allergic reactions. We have been using histaglobulin injection for treatment and curtailment of chronic urticaria effectively for the last two years, in addition to oral antihistamines. Objective This study aims to analyze the effect of treatment with injection of histaglobulin in patients of CIU from the data recorded in the Dermatology Outpatient Department (OPD) of C.U. Shah Medical College and Hospital, Surendranagar, Gujarat (CUSMC). Methods This is an observational retrospective review of patients with CIU treated with weekly histaglobulin injections coming to the Dermatology Department CUSMC from April 2022 to April 2024. The recorded data of 45 patients were assessed with more than six weeks of urticaria. Histglobulin injection was given subcutaneously near the deltoid region weekly for eight weeks. The Urticaria Activity Score (UAS) was recorded at each visit. A complete blood count (CBC) and serum immunoglobulin E (IgE) were done to rule out infection and allergic diathesis. The patient's history was taken to rule out other causes of urticaria. An oral non-sedative antihistaminic and soothing lotion (calamine lotion) was given to alleviate symptoms. Results Out of the 45 patients who underwent treatment with eight weekly injections, 28 completed therapy, 10 patients visited five to six times, and seven patients dropped treatment after two to three visits due to variable reasons. The UAS gradually decreased to lower levels after sequential injections of histaglobulin in all the patients who continued and completed the treatment protocol. Conclusion Our study shows a reduction of UAS in patients taking weekly histaglobulin injections. Histoglobulin significantly benefited patients suffering from the distress associated with urticaria. They had reduced dependence on oral antihistamines, and the frequency of visits to the hospital diminished.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.